Pagniez, F.
Professeur
Publications
P302
Inorg. Chem., 2025, 64, 16192-16203.
Synthesis and Biological Evaluation of Itraconazole Derivatives: Design in an Old Scaffold.
https://doi.org/10.1021/acs.inorgchem.5c02730
P300
RSC Med. Chem. 2025, 16, 3746–3763.
Pharmacophore-guided optimization of the hit compound CTN1122 in the design of promising imidazo[1,2-a]pyrazine derivatives targeting the casein kinase 1 for antileishmanial therapy
https://doi.org/10.1039/D5MD00257E
P290
ChemMedChem. 2025, 20, e202400862.
Investigating the C2 modulation of the imidazo[1,2-a]pyrazine-based hit compound CTN1122: synthesis, in vitro antileishmanial activity, cytotoxicity and casein kinase 1 inhibition.
https://doi.org/10.1002/cmdc.202400862
P280
Chem. Biodiversity 2024, e202300563
Chemical Composition, Antifungal, Antioxidant, and Hemolytic Activities of Morrocan Thymus capitatus Essential Oil.
https://doi.org/10.1002/cbdv.202300563
P271
J. Med. Chem. 2023.
Discovery of new broad-spectrum anti-infectives for eukaryotic pathogens using boorganometallic chemistry.
https://doi.org/10.1021/acs.jmedchem.3c01333
P249
PLoS One 2022.
CRISPR-Cas9 approach confirms Calcineurin-responsive zinc finger 1 (Crz1) transcription factor as a promising therapeutic target in echinocandin-resistant Candida glabrata.
https://doi.org/10.1371/journal.pone.0265777
P246
Microorganisms. 2022, 10, 104.
Impact of TR34/L98H, TR46/Y121F/T289A and TR53 alterations in azole‐resistant Aspergillus fumigatus on sterol composition and modifications after In Vitro exposure to itraconazole and voriconazole.
https://doi.org/10.3390/microorganisms10010104
P234
Med. Chem. Res. 2021, 30, 152-162.
Antimicrobial and anti-leishmanial activities of extracts and some constituents from the leaves of Solanum chrysotrichum Schldl.
doi: 10.1007/s00044-020-02648-8
P231
Eur. J. Med. Chem. 2021, 210, 112956.
In vitro identification of imidazo[1,2-a]pyrazine-based antileishmanial agents and evaluation of L. major casein kinase 1 inhibition.
doi: 10.1016/j.ejmech.2020.112956
P223
Pharmaceuticals. 2020, 13, 186.
Optimization, Antifungal Activity, Selectivity, and CYP51 Binding of New 2-Aryl-3-azolyl-1-indolyl-propan-2-ols.
doi:10.3390/ph13080186
P212
Eur. J. Med. Chem. 2020, 189, 112082.
New Azole Antifungals with a Fused Triazinone Scaffold.
doi: 10.1016/j.ejmech.2020.112082
P208
J. Enzym. Inhib. Med. Chem. 2020, 35, 398-403.
Biological exploration of a novel 1,2,4-triazole-indole hybrid molecule as antifungal agent.
doi: 10.1080/14756366.2019.1705292
P146
Med. Mycol. 2016, 54, 764-775.
The amino acid substitution N136Y in Candida albicans sterol 14alpha-demethylase is involved in fluconazole resistance.
doi: 10.1093/mmy/myw023
P144
Eur. J. Pharm. Biopharm. 2016, 101, 137-144.
Econazole imprinted textiles with antifungal activity.
doi: 10.1016/j.ejpb.2016.02.003
P136
Eur. J. Med. Chem. 2015, 103, 381-395.
Synthesis, antileishmanial activity and cytotoxicity of 2,3-diaryl- and 2,3,8-trisubstituted imidazo[1,2-a]pyrazines.
doi: 10.1016/j.ejmech.2015.09.002
P134
J. Nanopharmaceutics Drug Delivery 2014, 2, 1-11.
Enhanced pulmonary administration of amphotericin B loaded in PEG-g-PLA nanoparticles: in vitro proof-of-concept and susceptibility against Candida spp. and Aspergillus spp.
P123
Int J. Antimicrob. Agents. 2013 Nov;42(5):410-5.
Deciphering azole resistance mechanisms with a focus on transcription factor-encoding genes TAC1, MRR1 and UPC2 in a set of fluconazole-resistant clinical isolates of Candida albicans.
P115
Phytochemistry Letters, 2013; 6(3):498-503.
Anti-AGEs and antiparasitic activity of an original prenylated isoflavonoid and flavanones isolated from Derris ferruginea.
P114
ACS Med. Chem. Lett., 2013, 4, 288-292.
Discovery of a novel broad-spectrum antifungal agent, derived from albaconazole.
P108
Eur. J. Med. Chem., 2012, 58, 543-556.
Synthesis and biological evaluation of 2,3-diarylimidazo[1,2-a]pyridines as antileishmanial agents.
Autres publications scientifiques
Brevets
B17.
Novel fused pyrimidone and triazinone derivatives containing bridged nitrogen, their process of preparation and their therapeutic uses as antifungal and/or antiparasitic agents.
PCT WO 2017/021178 A1, 9 février 2017.
B14.
Milieu, dispositif et procédé de test de la sensibilité d'un inoculum de champignons à un agent antifongique.
B9.
Antifungal and/or antiparasitic pharmaceutical composition and novel indole derivatives as active principle of such a composition.
Brevet US 2004067998 A1 publié le 8 avril 2004.
B8.
Antifungal and/or antiparasitic pharmaceutical composition and novel indole derivatives as active principle of such a composition.
Brevet CN 1473160A publié le 4 février 2004.
B7.
Procédé de détection de la sensibilité des levures aux antifongiques.
Brevet /FR 1 54 056 - A1 2003.
B6.
New azolyl-substituted indole derivatives and analogs, useful as antifungal and antiparasitic drugs effective e.g. against Candida albicans, Aspergillus fumigatus and Leishmania.
Brevet EP 1322638 publié le 2 juillet 2003.
B5.
Indole derivatives and their use as antifungal and/or antiparasitic agents.
Brevet CA 2 423 151 A1 publié le 21 mars 2003.
B2.
Antifungal and/or antiparasitic pharmaceutical composition and novel indole derivatives as active principle of such a composition.
Brevet PCT WO 02/24685 A1 déposé le 21 septembre 2001, publié le 28 mars 2002.
B1.
Composition pharmaceutique antifongique et/ou antiparasitaire et nouveaux dérivés de l'indole à titre de principes actifs d'une telle composition
Brevet FR 2 814 073 - A1 déposé le 21 septembre 2000, publié le 22 mars 2002.
Thèse
T07.
Evaluation et exploration des mécanismes d'action de nouveaux dérivés azolybenzylindoles antileishmaniens et antifongiques.
Nantes, 20 décembre 2001.